Skip to main content

Table 3 Mean, confidence intervals and change in outcome measures

From: Feasibility of group-based acceptance and commitment therapy for adolescents (AHEAD) with multiple functional somatic syndromes: a pilot study

Month

0

0,5

2

3

4

5

8

Change from baseline to FU (CI)

SRM From baseline to FU

Change from group start to FU (CI)

SRM from group start to FU

Outcome measure

Assessment

Baseline

PC

Group start

Module 4

Module 8

Module 9

End of treatment

Follow up meeting

3-month FU

    
 

Mean (CI)

Mean (CI)

Mean (CI)

Mean (CI)

Mean (CI)

Mean (CI)

Mean (CI)

    

Primary outcome

 SF-36, PPH

n = 6–20

33.8 (30.2;37.4)

X

37.1 (33.9;40.3)

X

41.0 (36.2;45.9)

39.9 (36.1;43.6)

42.7 (39.4;46.0)

8.9 (5.4;12.4)

0.91 (0.26;1.57)

5.6 (2.5;8.7)

0.94 (0.40;1.49)

Secondary outcomes

 BDS checklist

n = 6–21

44.5 (38.0;50.9)

X

39.0 (31.9;46.1)

X

40.4 (31.7;49.2)

35.5 (26.5;44.6)

36.3 (28.9;43.8)

−8.1 (−14.2;-2.0)

0.52 (− 0.08;1.13)

−2.7 (−9.7;4.4)

0.62 (− 0.26;1.51)

 LI

n = 6–21

21.9 (18.9;24.9)

17.9 (14.3;21.5)

18.9 (15.4;22.4)

22.2 (17.3;27.1)

16.4 (11.4;21.3)

16.1 (12.4;19.8)

15.5 (12.4;18.6)

−6.4 (−9.7;-3.2)

0.72 (0.21;1.23)

−3.4 (−7.1;0.3)

0.33 (− 0.23;0.89)

 WI-7

n = 12–21

2.0 (1.6;2.3)

X

1.5 (1.1;1.8)

X

1.2 (0.8;1.7)

1.0 (0.6;1.4)

1.0 (0.6;1.4)

−0.9 (−1.3;-0.6)

0.82 (0.30;1.34)

−0.4 (− 0.8;-0.1)

0.78 (0.26;1.30)

 SCL-8

n = 6–21

1.8 (1.4;2.2)

X

1.4 (0.8;2.0)

X

1.8 (1.3;2.4)

1.5 (1.0;1.9)

1.4 (1.0;1.8)

−0.5 (− 0.8;− 0.1)

0.49 (0.02;0.97)

-0.1 (− 0.6;0.5)

0.09 (− 0.71;0.89)

Treatment targets

 BRIQ, an

n = 6–20

17.9 (15.7;20.2)

X

19.3 (17.3;21.2)

19.3 (16.1;22.5)

17.6 (15.3;19.9)

16.1 (13.8;18.5)

15.1 (13.1;17.0)

−2.9 (−5.2;-0.4)

0.38 (−0.19;0.94)

−4.2 (−6.3;-2.0)

0.72 (0.21;1.22)

 BRIQ, li

n = 6–20

24.8 (22.4;27.3)

X

21.6 (19.4;23.8)

21.0 (17.6;24.4)

19.9 (17.4;22.5)

19.5 (16.9;22.0)

18.9 (16.6;21.1)

−6.0 (−8.4;-3.5)

1.00 (0.32;1.67)

−2.7 (−4.9;-0.6)

0.51 (0.03;0.99)

 IPQ

n = 6–21

55.5 (51.3;59.7)

X

50.8 (46.5;55.1)

53.2 (45.9;60.5)

40.0 (34.9;45.2)

43.1 (37.8;48.5)

35.8 (31.4;40.1)

−19.7 (−24.8;-14.6)

1.22 (0.62;1.82)

−15.0 (− 20.1;-9.9)

0.99 (0.44;1.55)

 AFQ-Y8

n = 6–20

12.0 (8.8;15.1)

X

13.5 (10.5;16.4)

14.4 (10.5;18.4)

11.8 (8.6;15.0)

9.5 (6.2;12.8)

8.9 (5.9;11.9)

−3.0 (−5.4;-0.6)

0.57 (−0.02;1.16)

−4.5 (−6.6;-2.4)

0.99 (0.43;1.54)

  1. Mean at different time points as well as change from baseline to follow-up and from group-start to follow up with inclusion of effect sizes
  2. Abbreviations alphabetically presented: AFQ-Y8 avoidance and fusion questionnaire, BDS bodily distress syndrome, BRIQ, AN behavioural response to illness questionnaire, all or nothing behaviour, BRIQ, LI behavioural response to illness questionnaire, limiting behaviour, CI: 95% confidence interval, FU follow up, IPQ illness perception questionnaire, LI limitation index, MCS mental component summary, PC psychiatric consultation, PCS physical component summary, PPH perceived physical health, SCL-8 symptom checklist, SE standard error, SRM standardized response mean, WI-7 whiteley-7, X no measurement
Back to article page

BMC Psychiatry

ISSN: 1471-244X

Contact us